Developing a treatment to inhibit STAT3 for lung scleroderma
Official title: The development of a STAT3 inhibitor for lung scleroderma
Funded at Altay Therapeutics, INC. · NIH-10922280 · Data updated 2026-11-12
This study is looking at a new treatment that could help people with lung scleroderma by targeting a protein called STAT3, which may help reduce lung inflammation and improve breathing and overall well-being.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Altay Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Carlos, UNITED STATES) |
| Project start | May 15, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $299,999 |
| NIH project number | 1R43HL172594-01A1 |
| Project ID | NIH-10922280 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with lung scleroderma who are experiencing significant lung-related symptoms.
✕Less likely to help
Patients with scleroderma who do not have lung involvement or those who have already undergone lung transplantation may not benefit from this research.
What this research studies
This research focuses on creating a new treatment that targets the STAT3 protein, which is known to play a significant role in the progression of lung scleroderma, an autoimmune disorder. By inhibiting STAT3, the research aims to reduce inflammation and fibrosis in the lungs, potentially improving lung function and quality of life for patients. The approach involves studying patient samples and using experimental models to understand how blocking STAT3 can affect disease progression. If successful, this treatment could offer a new therapeutic option for patients suffering from this challenging condition.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that slows down or reverses lung damage in patients with scleroderma.
How similar studies have gone: Previous studies have shown promise in targeting STAT3 for treating fibrosis in other conditions, indicating potential success for this approach in scleroderma.
Where this research is happening
-
Altay Therapeutics, INC.
San Carlos, United States Active
Researchers
- Principal investigator: Ozes, Ali Rayet — Altay Therapeutics, INC.
- Study coordinator: Ozes, Ali Rayet
Related research
Other NIH-funded projects on the same topics.
-
Angiogenesis imaging in scleroderma to track digital ulcers
A patient-friendly look at using a special imaging tracer to watch blood vessel growth in the hands of people with scleroderma to help manage digital ulcers.
-
Cell-level clues to skin scarring in systemic sclerosis and localized scleroderma
A study at the University of Pittsburgh is looking at how skin cells and their helpers change at the DNA level in adults and children with systemic sclerosis to find new targets to reduce scarring.
-
Pediatric Scleroderma: Mapping Cells and Tissues to Personalize Care
A study will map the different cell types and tissue patterns in skin from children with scleroderma to identify patient-specific disease subtypes that could guide targeted therapies.
-
CD38 and NAD metabolism in scleroderma (systemic sclerosis) fibrosis
This grant explores how changes in NAD metabolism related to CD38 and NNMT may drive scarring in systemic sclerosis and tests new ways to stop it.
-
ISG15-positive monocytes and SPP1 macrophages in scleroderma lung disease
This grant studies a specific immune cell pathway in systemic sclerosis with lung scarring to help predict how the disease progresses.
-
Autoantibodies define scleroderma subgroups with distinct cancer links
Researchers are studying how specific autoantibodies in scleroderma patients relate to cancer timing and risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.